You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVincristine
Accession NumberDB00541  (APRD00495)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionVincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
Structure
Thumb
Synonyms
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
Leurocristine
Vincristin
Vincristina
Vincristinum
External Identifiers
  • L 37231
  • NSC 67574
  • VCR
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MarqiboKitTalon Therapeutics, Inc.2013-01-14Not applicableUs
Oncovin Solution 1mg/mlLiquid1 mgIntravenousEli Lilly Canada Inc1984-12-311998-08-04Canada
Vincristine Sulfate Inj 1mg/ml USPLiquid1 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311999-08-10Canada
Vincristine Sulfate Inj 5mg/vial USPPowder, for solution5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1989-12-311996-09-10Canada
Vincristine Sulfate InjectionSolution1 mgIntravenousTeva Canada Limited1995-12-31Not applicableCanada
Vincristine Sulfate InjectionSolution1 mgIntravenousAccord Healthcare IncNot applicableNot applicableCanada
Vincristine Sulfate Injection USPSolution1 mgIntravenousHospira Healthcare Corporation1997-08-07Not applicableCanada
Vincristine Sulfate Injection USPSolution1 mgIntravenousUman Pharma IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vincasar PFSInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
Vincasar PFSInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.2000-05-01Not applicableUs
Vincristine SulfateInjection, solution1 mg/mLIntravenousHospira Worldwide, Inc.1988-04-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlcavixinKorea United Pharma
AlcristAlkem
CitomidCSC
CytocristinCipla
OncocristinSun
OncovinLilly
OncrivinTeva
SindovinActavis
TevacristinTeva
VincesIvax
VincrisinTeva
VincristinGedeon Richter
VincrisulSTADA
VinlonCelon
VinracineMeizler
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vincristine Sulfate
2068-78-2
Thumb
  • InChI Key: AQTQHPDCURKLKT-VEGNXYBXSA-N
  • Monoisotopic Mass: 922.367023274
  • Average Mass: 923.036
DBSALT000314
Categories
UNII5J49Q6B70F
CAS number57-22-7
WeightAverage: 824.9576
Monoisotopic: 824.399644032
Chemical FormulaC46H56N4O10
InChI KeyOGWKCGZFUXNPDA-XQKSVPLYSA-N
InChI
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([[email protected]](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
Pharmacology
IndicationTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
Structured Indications Not Available
PharmacodynamicsVincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Mechanism of actionThe antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin beta chainProteinyes
inhibitor
HumanP07437 details
Tubulin alpha-4A chainProteinunknown
inhibitor
HumanP68366 details
Related Articles
AbsorptionNot Available
Volume of distribution

Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.

Protein binding~75%
Metabolism

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine.

Route of eliminationThe liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine.
Half lifeWhen intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.
ClearanceNot Available
ToxicityIVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg. Marqibo® must only be administered IV because it is fatal if administered by other routes. Marqibo® also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically significant adverse effect of vincristine is neurotoxicity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Vincristine Action PathwayDrug actionSMP00437
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Vincristine.Approved
AcetaminophenThe serum concentration of Vincristine can be increased when it is combined with Acetaminophen.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Vincristine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vincristine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Vincristine.Approved, Vet Approved
AfatinibThe serum concentration of Vincristine can be increased when it is combined with Afatinib.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Vincristine.Approved
AlbendazoleThe serum concentration of Vincristine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Vincristine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Vincristine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Vincristine can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Vincristine.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Vincristine is combined with ALT-110.Investigational
AmantadineThe serum concentration of Vincristine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Vincristine.Approved, Investigational
Aminohippuric acidThe serum concentration of Vincristine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.Approved, Investigational
AmiodaroneThe metabolism of Vincristine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Vincristine can be increased when it is combined with Amitriptyline.Approved
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Vincristine.Approved
AmlodipineThe serum concentration of Vincristine can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Vincristine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Vincristine can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Vincristine.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Vincristine.Approved
AprepitantThe serum concentration of Vincristine can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.Approved, Investigational
AstemizoleThe serum concentration of Vincristine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Vincristine can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Vincristine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Vincristine can be increased when it is combined with Atenolol.Approved
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Vincristine.Approved
AtomoxetineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Vincristine can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Vincristine.Approved, Investigational
AzelastineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Vincristine can be increased when it is combined with Azithromycin.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Vincristine.Investigational
BenzocaineThe serum concentration of Vincristine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Vincristine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Vincristine.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Vincristine.Approved, Investigational
BexaroteneThe serum concentration of Vincristine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Vincristine can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Vincristine can be increased when it is combined with Boceprevir.Approved
BoceprevirThe metabolism of Vincristine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Vincristine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vincristine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Vincristine can be increased when it is combined with Bosutinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vincristine.Approved
BromocriptineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.Approved, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.Approved, Investigational
BuprenorphineThe serum concentration of Vincristine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Vincristine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vincristine.Approved
CaffeineThe serum concentration of Vincristine can be increased when it is combined with Caffeine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Vincristine.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Vincristine.Experimental
CanagliflozinThe serum concentration of Vincristine can be increased when it is combined with Canagliflozin.Approved
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Vincristine.Approved
CandesartanThe serum concentration of Vincristine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Vincristine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Vincristine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Vincristine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Vincristine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Vincristine.Approved
CarvedilolThe serum concentration of Vincristine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Vincristine can be increased when it is combined with Caspofungin.Approved
CDX-110The risk or severity of adverse effects can be increased when Vincristine is combined with CDX-110.Investigational
CeritinibThe serum concentration of Vincristine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Vincristine.Withdrawn
ChloroquineThe serum concentration of Vincristine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vincristine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Vincristine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Vincristine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Vincristine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Vincristine can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Vincristine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Vincristine.Approved
CitalopramThe serum concentration of Vincristine can be increased when it is combined with Citalopram.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Vincristine.Approved
ClarithromycinThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.Approved
ClarithromycinThe metabolism of Vincristine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vincristine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Vincristine.Approved, Illicit
ClofazimineThe serum concentration of Vincristine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Vincristine.Approved, Investigational
ClomipramineThe serum concentration of Vincristine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Vincristine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Vincristine.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Vincristine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClotrimazoleThe metabolism of Vincristine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Vincristine.Approved
CobicistatThe serum concentration of Vincristine can be increased when it is combined with Cobicistat.Approved
CobicistatThe metabolism of Vincristine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Vincristine.Approved
ColchicineThe serum concentration of Vincristine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Vincristine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Vincristine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Vincristine.Approved
CrizotinibThe serum concentration of Vincristine can be increased when it is combined with Crizotinib.Approved
CrizotinibThe metabolism of Vincristine can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vincristine.Approved, Investigational
CyclosporineThe serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Vincristine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.Approved
DabrafenibThe serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Vincristine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Vincristine can be increased when it is combined with Dactinomycin.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Vincristine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Vincristine.Approved
DarunavirThe serum concentration of Vincristine can be increased when it is combined with Darunavir.Approved
DarunavirThe metabolism of Vincristine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Vincristine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Vincristine.Approved
DeferasiroxThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Vincristine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.Approved
DesipramineThe serum concentration of Vincristine can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vincristine.Approved
DesloratadineThe serum concentration of Vincristine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Vincristine can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Vincristine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Vincristine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vincristine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vincristine.Approved
DigoxinThe serum concentration of Vincristine can be decreased when it is combined with Digoxin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Vincristine.Approved
DihydroergotamineThe serum concentration of Vincristine can be increased when it is combined with Dihydroergotamine.Approved
DihydroergotamineThe metabolism of Vincristine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Vincristine.Illicit
DiltiazemThe serum concentration of Vincristine can be increased when it is combined with Diltiazem.Approved
DiltiazemThe metabolism of Vincristine can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Vincristine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Vincristine.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Vincristine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Vincristine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vincristine.Approved, Investigational
DoxycyclineThe metabolism of Vincristine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Vincristine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Vincristine can be increased when it is combined with Dronedarone.Approved
DronedaroneThe metabolism of Vincristine can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vincristine.Approved
EfavirenzThe serum concentration of Vincristine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Vincristine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Vincristine.Approved, Investigational
EltrombopagThe serum concentration of Vincristine can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Vincristine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Vincristine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Vincristine.Approved, Investigational
ErgonovineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Vincristine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Vincristine.Approved, Investigational
ErythromycinThe serum concentration of Vincristine can be decreased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe serum concentration of Vincristine can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Vincristine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Vincristine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Vincristine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Vincristine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Vincristine can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vincristine.Approved
EtoposideThe serum concentration of Vincristine can be increased when it is combined with Etoposide.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Vincristine.Approved
EtravirineThe serum concentration of Vincristine can be increased when it is combined with Etravirine.Approved
EtravirineThe serum concentration of Vincristine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vincristine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Vincristine.Approved
FelodipineThe serum concentration of Vincristine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Vincristine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.Approved
FexofenadineThe serum concentration of Vincristine can be increased when it is combined with Fexofenadine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Vincristine.Approved
FidaxomicinThe serum concentration of Vincristine can be increased when it is combined with Fidaxomicin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Vincristine.Approved
FingolimodVincristine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Vincristine can be increased when it is combined with Fluconazole.Approved
FluconazoleThe metabolism of Vincristine can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Vincristine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Vincristine can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vincristine.Approved
FluvoxamineThe serum concentration of Vincristine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FluvoxamineThe metabolism of Vincristine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vincristine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vincristine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Vincristine can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vincristine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Vincristine is combined with G17DT.Investigational
GefitinibThe serum concentration of Vincristine can be increased when it is combined with Gefitinib.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Vincristine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Vincristine.Approved
GenisteinThe serum concentration of Vincristine can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Vincristine is combined with GI-5005.Investigational
GlyburideThe serum concentration of Vincristine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Vincristine can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Vincristine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Vincristine.Approved
GrepafloxacinThe serum concentration of Vincristine can be increased when it is combined with Grepafloxacin.Withdrawn
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Vincristine.Withdrawn
HaloperidolThe serum concentration of Vincristine can be increased when it is combined with Haloperidol.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Vincristine.Approved
HydrocortisoneThe serum concentration of Vincristine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Vincristine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Vincristine.Approved
IdelalisibThe serum concentration of Vincristine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Vincristine can be increased when it is combined with Imatinib.Approved
ImatinibThe metabolism of Vincristine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Vincristine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Vincristine.Approved
IndinavirThe serum concentration of Vincristine can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Vincristine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Vincristine can be increased when it is combined with Indomethacin.Approved, Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Vincristine.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Vincristine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Vincristine is combined with INGN 225.Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Vincristine.Approved, Investigational
IsavuconazoniumThe serum concentration of Vincristine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsavuconazoniumThe metabolism of Vincristine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Vincristine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Vincristine can be increased when it is combined with Itraconazole.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vincristine.Approved, Investigational
IvacaftorThe serum concentration of Vincristine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Vincristine can be increased when it is combined with Ivermectin.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Vincristine.Approved, Vet Approved
JosamycinThe serum concentration of Vincristine can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Vincristine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Vincristine.Approved
KetoconazoleThe serum concentration of Vincristine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Vincristine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Vincristine can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Vincristine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Vincristine.Approved, Investigational
LansoprazoleThe serum concentration of Vincristine can be increased when it is combined with Lansoprazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Vincristine.Approved, Investigational
LapatinibThe serum concentration of Vincristine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Vincristine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Vincristine is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Vincristine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Vincristine.Approved, Investigational
LevofloxacinThe serum concentration of Vincristine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Vincristine.Approved
LevothyroxineThe serum concentration of Vincristine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Vincristine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Vincristine.Approved
LiothyronineThe serum concentration of Vincristine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Vincristine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Vincristine can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Vincristine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Vincristine can be increased when it is combined with Loperamide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Vincristine.Approved
LopinavirThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Vincristine can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Vincristine can be increased when it is combined with Losartan.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Vincristine.Approved
LovastatinThe serum concentration of Vincristine can be increased when it is combined with Lovastatin.Approved, Investigational
LovastatinThe metabolism of Vincristine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vincristine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Vincristine can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Vincristine.Approved, Investigational
MaprotilineThe serum concentration of Vincristine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Vincristine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Vincristine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Vincristine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Vincristine can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Vincristine can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Vincristine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.Approved, Vet Approved
MetoprololThe serum concentration of Vincristine can be increased when it is combined with Metoprolol.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Vincristine.Approved, Investigational
MibefradilThe serum concentration of Vincristine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Vincristine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Vincristine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Vincristine can be decreased when it is combined with Mifepristone.Approved, Investigational
MifepristoneThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Vincristine.Approved
MitomycinThe serum concentration of Vincristine can be increased when it is combined with Mitomycin.Approved
MitomycinThe risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Vincristine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Vincristine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Vincristine can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Vincristine can be increased when it is combined with Morphine.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Vincristine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Vincristine.Approved
NafcillinThe serum concentration of Vincristine can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vincristine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Vincristine.Approved, Vet Approved
NaltrexoneThe serum concentration of Vincristine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Vincristine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NefazodoneThe metabolism of Vincristine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vincristine can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Vincristine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Vincristine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Vincristine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Vincristine can be decreased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Vincristine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Vincristine.Approved
NifedipineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Vincristine can be increased when it is combined with Nilotinib.Approved, Investigational
NilotinibThe metabolism of Vincristine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vincristine.Approved
NisoldipineThe serum concentration of Vincristine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Vincristine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Vincristine.Approved
NorethisteroneThe serum concentration of Vincristine can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Vincristine.Approved, Investigational
OlaparibThe metabolism of Vincristine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Vincristine can be increased when it is combined with Oleandomycin.Vet Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Vincristine.Approved
OmeprazoleThe serum concentration of Vincristine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Vincristine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vincristine.Approved
P-NitrophenolThe serum concentration of Vincristine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.Approved, Vet Approved
PalbociclibThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Vincristine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Vincristine.Approved, Investigational
PantoprazoleThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.Approved
PentobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe metabolism of Vincristine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Vincristine can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Vincristine can be decreased when it is combined with Phenobarbital.Approved
PhenobarbitalThe metabolism of Vincristine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Vincristine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.Approved, Investigational
PimozideThe serum concentration of Vincristine can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Vincristine.Approved
Platelet Activating FactorThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Vincristine.Approved
PonatinibThe serum concentration of Vincristine can be increased when it is combined with Ponatinib.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Vincristine.Approved
PosaconazoleThe serum concentration of Vincristine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vincristine.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Vincristine can be increased when it is combined with Pravastatin.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Vincristine.Approved
PrazosinThe serum concentration of Vincristine can be increased when it is combined with Prazosin.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Vincristine.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.Approved, Vet Approved
PrednisoneThe serum concentration of Vincristine can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Vincristine.Approved, Vet Approved
PrimidoneThe serum concentration of Vincristine can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Vincristine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Vincristine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Vincristine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Vincristine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Vincristine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Vincristine can be increased when it is combined with Propranolol.Approved, Investigational
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Vincristine.Approved, Investigational
ProtriptylineThe serum concentration of Vincristine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vincristine.Approved
QuercetinThe serum concentration of Vincristine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.Approved
QuinacrineThe serum concentration of Vincristine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Vincristine can be increased when it is combined with Quinidine.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Vincristine.Approved
QuinineThe serum concentration of Vincristine can be increased when it is combined with Quinine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Vincristine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Vincristine is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Vincristine.Approved
RanitidineThe serum concentration of Vincristine can be increased when it is combined with Ranitidine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Vincristine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vincristine.Approved, Investigational
ReboxetineThe serum concentration of Vincristine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Vincristine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Vincristine can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Vincristine can be decreased when it is combined with Rifabutin.Approved
RifabutinThe metabolism of Vincristine can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Vincristine can be decreased when it is combined with Rifampicin.Approved
RifampicinThe metabolism of Vincristine can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Vincristine can be decreased when it is combined with Rifapentine.Approved
RifapentineThe metabolism of Vincristine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vincristine.Approved, Investigational
RilpivirineThe serum concentration of Vincristine can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Vincristine.Approved, Investigational
RitonavirThe serum concentration of Vincristine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Vincristine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Vincristine.Approved
RolapitantThe serum concentration of Vincristine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Vincristine.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Vincristine.Approved, Vet Approved
SaquinavirThe serum concentration of Vincristine can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Vincristine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Vincristine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Vincristine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Vincristine.Approved
SertralineThe serum concentration of Vincristine can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Vincristine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vincristine.Approved
SiltuximabThe serum concentration of Vincristine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vincristine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Vincristine can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vincristine.Approved
SirolimusThe serum concentration of Vincristine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Vincristine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Vincristine.Approved
SolithromycinThe serum concentration of Vincristine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Vincristine can be increased when it is combined with Sorafenib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Vincristine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Vincristine.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Vincristine.Experimental
SpiramycinThe serum concentration of Vincristine can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe serum concentration of Vincristine can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Vincristine is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Vincristine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Vincristine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Vincristine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Vincristine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Vincristine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Vincristine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Vincristine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Vincristine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Vincristine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Vincristine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vincristine.Approved, Investigational
TamoxifenThe serum concentration of Vincristine can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Vincristine can be increased when it is combined with Taurocholic Acid.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vincristine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Vincristine.Approved
TelaprevirThe serum concentration of Vincristine can be increased when it is combined with Telaprevir.Approved
TelaprevirThe metabolism of Vincristine can be decreased when combined with Telaprevir.Approved
TelithromycinThe serum concentration of Vincristine can be increased when it is combined with Telithromycin.Approved
TelithromycinThe metabolism of Vincristine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.Approved
TeniposideTeniposide may increase the neurotoxic activities of Vincristine.Approved
TerazosinThe serum concentration of Vincristine can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Vincristine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Vincristine can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Vincristine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Vincristine can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Vincristine is combined with TG4010.Investigational
TicagrelorThe serum concentration of Vincristine can be increased when it is combined with Ticagrelor.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Vincristine.Approved
TiclopidineThe metabolism of Vincristine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Vincristine.Approved
TocilizumabThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibVincristine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Vincristine can be increased when it is combined with Tolvaptan.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Vincristine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vincristine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Vincristine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vincristine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Vincristine.Approved
TrazodoneThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Vincristine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Vincristine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Vincristine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Vincristine can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Vincristine can be increased when it is combined with Tylosin.Vet Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Vincristine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Vincristine.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Vincristine.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Vincristine.Approved
VenlafaxineThe serum concentration of Vincristine can be increased when it is combined with Venlafaxine.Approved
VenlafaxineThe metabolism of Vincristine can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Vincristine can be decreased when it is combined with Verapamil.Approved
VerapamilThe metabolism of Vincristine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vincristine can be decreased when it is combined with Vinblastine.Approved
VinorelbineThe serum concentration of Vincristine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Vincristine.Approved
VoriconazoleThe serum concentration of Vincristine can be increased when it is combined with Voriconazole.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vincristine.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Vincristine.Approved
ZimelidineThe serum concentration of Vincristine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Vincristine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Homer L. Pearce, “Method of preparing vincristine.” U.S. Patent US4303584, issued November, 1967.

US4303584
General References
  1. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62. [PubMed:8608515 ]
  2. Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3. [PubMed:17355029 ]
  3. JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427. [PubMed:14070392 ]
  4. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87. [PubMed:10226730 ]
External Links
ATC CodesL01CA02
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (362 KB)
MSDSDownload (90.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9738
Blood Brain Barrier-0.9514
Caco-2 permeable+0.6262
P-glycoprotein substrateSubstrate0.9027
P-glycoprotein inhibitor IInhibitor0.6573
P-glycoprotein inhibitor IIInhibitor0.6919
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8071
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7666
CYP450 1A2 substrateNon-inhibitor0.9203
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7491
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8574
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8938
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9324 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9699
hERG inhibition (predictor II)Inhibitor0.5265
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Teva parenteral medicines inc
  • Bristol myers squibb
  • Abic ltd
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Kit
LiquidIntravenous1 mg
Injection, solutionIntravenous1 mg/mL
Powder, for solutionIntravenous5 mg
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Vincristine 2 mg/2 ml vial18.06USD ml
Oncovite tablet0.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723338 No2000-03-312020-03-31Us
US7247316 No2000-09-252020-09-25Us
US7887836 No2000-03-312020-03-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220 °CPhysProp
logP2.82HANSCH,C ET AL. (1995)
pKa5MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.03 mg/mLALOGPS
logP3.36ALOGPS
logP3.13ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)10.85ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area171.17 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity221.48 m3·mol-1ChemAxon
Polarizability88.59 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassVinca alkaloids
Sub ClassNot Available
Direct ParentVinca alkaloids
Alternative Parents
Substituents
  • Vinca alkaloid skeleton
  • Carbazole
  • Indole or derivatives
  • Indole
  • Anisole
  • Aralkylamine
  • Tetrahydropyridine
  • Alkyl aryl ether
  • Benzenoid
  • N-alkylpyrrolidine
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Acetate salt
  • Methyl ester
  • Tertiary carboxylic acid amide
  • Tertiary alcohol
  • Pyrrolidine
  • Pyrrole
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB
Uniprot ID:
P07437
Molecular Weight:
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10. [PubMed:19277662 ]
  4. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA4A
Uniprot ID:
P68366
Molecular Weight:
49923.995 Da
References
  1. Yasui M, Koyama N, Koizumi T, Senda-Murata K, Takashima Y, Hayashi M, Sugimoto K, Honma M: Live cell imaging of micronucleus formation and development. Mutat Res. 2010 Oct 13;692(1-2):12-8. doi: 10.1016/j.mrfmmm.2010.07.009. Epub 2010 Aug 5. [PubMed:20691709 ]
  2. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. [PubMed:20442307 ]
  3. Vilpo JA, Koski T, Vilpo LM: Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000 Dec;65(6):370-8. [PubMed:11168494 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73. [PubMed:12490309 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  4. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. [PubMed:9862789 ]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  6. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
  7. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  8. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674 ]
  9. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050 ]
  10. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  11. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644 ]
  2. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726 ]
  3. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490 ]
  4. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Akiyama SI: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol. 1997 Mar;51(3):399-405. [PubMed:9058594 ]
  5. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M: ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol. 1999 Feb;126(3):681-8. [PubMed:10188979 ]
  6. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
  2. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem. 1990 Nov 5;265(31):19279-86. [PubMed:2172249 ]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Molecular Weight:
76062.86 Da
References
  1. Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, Awasthi S: RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol. 2007 Jan;30(1):139-44. [PubMed:17143522 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40